Achilles Therapeutics (ACHL) Competitors $1.07 +0.02 (+1.90%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ACHL vs. BDTX, NLTX, DMAC, ADAP, ACTU, HRTX, GOSS, GALT, SCPH, and OGIShould you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Black Diamond Therapeutics (BDTX), Neoleukin Therapeutics (NLTX), DiaMedica Therapeutics (DMAC), Adaptimmune Therapeutics (ADAP), Actuate Therapeutics (ACTU), Heron Therapeutics (HRTX), Gossamer Bio (GOSS), Galectin Therapeutics (GALT), scPharmaceuticals (SCPH), and Organigram (OGI). These companies are all part of the "pharmaceutical products" industry. Achilles Therapeutics vs. Black Diamond Therapeutics Neoleukin Therapeutics DiaMedica Therapeutics Adaptimmune Therapeutics Actuate Therapeutics Heron Therapeutics Gossamer Bio Galectin Therapeutics scPharmaceuticals Organigram Black Diamond Therapeutics (NASDAQ:BDTX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability. Does the media refer more to BDTX or ACHL? In the previous week, Achilles Therapeutics had 6 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 7 mentions for Achilles Therapeutics and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.92 beat Achilles Therapeutics' score of -0.01 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Achilles Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, BDTX or ACHL? Black Diamond Therapeutics has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Do insiders and institutionals hold more shares of BDTX or ACHL? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate BDTX or ACHL? Black Diamond Therapeutics presently has a consensus target price of $15.50, suggesting a potential upside of 537.86%. Achilles Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 273.83%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Achilles Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Achilles Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, BDTX or ACHL? Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$82.44M-$1.33-1.83Achilles TherapeuticsN/AN/A-$69.67M-$1.65-0.65 Does the MarketBeat Community favor BDTX or ACHL? Black Diamond Therapeutics received 34 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% Achilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Is BDTX or ACHL more profitable? Achilles Therapeutics' return on equity of -54.45% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% Achilles Therapeutics N/A -54.45%-47.68% SummaryBlack Diamond Therapeutics beats Achilles Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Achilles Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHL vs. The Competition Export to ExcelMetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.98M$2.93B$5.06B$8.82BDividend YieldN/A1.89%5.17%4.07%P/E Ratio-0.6545.62125.9917.81Price / SalesN/A359.341,180.3874.38Price / CashN/A160.0933.8232.53Price / Book0.313.734.684.68Net Income-$69.67M-$41.63M$119.54M$226.08M7 Day Performance4.90%-7.95%-2.45%-2.04%1 Month Performance7.00%-7.17%-4.06%0.06%1 Year Performance32.10%23.03%29.86%24.60% Achilles Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHLAchilles Therapeutics2.3832 of 5 stars$1.07+1.9%$4.00+273.8%+32.1%$43.98MN/A-0.65250BDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.49+2.5%$15.50+522.5%+8.0%$140.88MN/A0.0090Positive NewsNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeDMACDiaMedica Therapeutics1.902 of 5 stars$4.02-0.5%$7.00+74.1%+62.8%$171.90MN/A0.0020ADAPAdaptimmune Therapeutics2.1006 of 5 stars$0.67+0.8%$3.16+372.0%+54.9%$171.44M$60.28M0.00449Analyst RevisionACTUActuate TherapeuticsN/A$8.67-2.6%N/AN/A$169.33MN/A0.0010HRTXHeron Therapeutics3.9688 of 5 stars$1.11-0.9%$5.67+410.5%-13.8%$168.83M$127.04M0.00300Analyst DowngradeShort Interest ↓GOSSGossamer Bio4.4297 of 5 stars$0.75+7.0%$9.20+1,134.9%-16.9%$168.82MN/A-2.18180GALTGalectin Therapeutics1.6982 of 5 stars$2.68-5.0%$11.00+310.4%+50.8%$168.20MN/A0.009Analyst UpgradeAnalyst RevisionNews CoverageSCPHscPharmaceuticals3.8122 of 5 stars$3.36-4.5%$15.00+346.4%-40.2%$168.13M$13.59M0.0030Analyst RevisionOGIOrganigram0.469 of 5 stars$1.50+1.4%N/A+16.5%$163.38M$120.01M-3.52860 Related Companies and Tools Related Companies BDTX Alternatives NLTX Alternatives DMAC Alternatives ADAP Alternatives ACTU Alternatives HRTX Alternatives GOSS Alternatives GALT Alternatives SCPH Alternatives OGI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACHL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
